Target Ferritin Level for Hair Loss
For women with hair loss, aim for a serum ferritin level of at least 40-70 ng/mL, with optimal levels likely around 70 ng/mL or higher, though the evidence supporting iron supplementation improving hair regrowth remains uncertain.
The Evidence Landscape
The relationship between iron deficiency and hair loss is controversial and the data are conflicting. The most relevant guideline addressing this issue is the 2019 Androgen Excess and PCOS Committee report on female pattern hair loss 1. This guideline acknowledges that while some studies show lower ferritin levels in women with hair loss (particularly those with the most severe hair loss), other well-designed studies found no significant association between iron deficiency and female pattern hair loss (FPHL) or chronic telogen effluvium.
Critically, one study cited in the guideline found that iron supplementation in patients with low-normal serum ferritin (<70 ng/mL) did not improve hair loss 1. The guideline concludes there is "an uncertain relationship of iron deficiency and FPHL" and notes the lack of well-controlled studies demonstrating that correcting iron deficiency actually improves hair loss 1.
Practical Target Levels
Despite the uncertain evidence, several sources suggest specific ferritin thresholds:
Research-Based Targets:
70 ng/mL: A 1993 study suggested serum ferritin concentrations of 70 ng/mL or greater represent optimal hair growth potential 2. A 2010 review recommended targeting 70 μg/L when hair loss is unexplained 3.
40-60 ng/mL: A 2023 study from Taiwan defined adequate ferritin levels for hair growth as 40-60 ng/mL, corresponding to hemoglobin levels of 13.1-13.8 g/dL 4. This study found that 70.3% of female alopecia cases had iron deficiency when defined as ferritin <60 ng/mL.
Recent hair loss correlation: A 2022 study found iron deficiency (ferritin ≤20 µg/L) was significantly correlated with recent hair loss in non-anemic women 5.
Diagnostic Thresholds:
The evidence shows varying cut-off values for defining iron deficiency in hair loss:
- Studies have used thresholds ranging from <15 ng/mL to <70 ng/mL 1
- A 2013 study suggested cut-off values of 27.5 μg/L for telogen effluvium and 29.4 μg/L for FPHL 6
Clinical Algorithm
Step 1: Measure baseline ferritin
- If ferritin <40 ng/mL: Clear iron deficiency; supplement
- If ferritin 40-70 ng/mL: Consider supplementation, especially if other causes excluded
- If ferritin >70 ng/mL: Iron deficiency unlikely to be contributing
Step 2: Consider inflammatory conditions
- In patients with inflammatory bowel disease or chronic inflammation, ferritin up to 100 μg/L may still indicate iron deficiency 7
- Use additional markers (transferrin saturation, C-reactive protein) if inflammation suspected 8, 9
Step 3: Timing matters
- The 2023 Taiwan study found that initiating iron supplementation within 6 months of hair loss onset resulted in better prognosis 4
- Disease duration was an important prognostic factor for ferritin improvement
Step 4: Monitor response
- Recheck ferritin every 3 months 4
- Target ferritin ≥60 ng/mL based on the most recent evidence 4
- Patients with subjective hair regrowth showed greater increases in ferritin levels
Important Caveats
The fundamental limitation: The 2019 guideline emphasizes that "well-controlled studies are needed to establish the relatedness of these deficiencies to FPHL and whether correction of the deficiency specifically improves hair growth" 1. One study explicitly showed no improvement with supplementation at ferritin <70 ng/mL 1.
Don't over-supplement: While targeting higher ferritin levels seems reasonable based on observational data, there is no strong evidence that iron supplementation actually improves hair loss outcomes. The association between low ferritin and hair loss does not prove causation.
Rule out other causes first: The guideline recommends measuring blood iron studies, vitamin D, zinc, thyroid profile, and prolactin to rule out other treatable conditions 1. A 2023 study found diverse etiologies including autoimmune diseases (14.8%), thyroid disease (7.7%), psychological stress (12.3%), and COVID-19 vaccination (6.5%) 4.
First-line treatment remains topical minoxidil: The guideline clearly states that topical minoxidil is considered first-line treatment for female pattern hair loss, with the strongest evidence base 1.